Paper of the Month from the ESC Working Group on Thrombosis

Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Membership

Commented papers on Thrombosis

Published by the ESC Working Group on Thrombosis

This section includes a selection of interesting papers explained and commented by members of the Working Group on Thrombosis.

The papers are first sent out to Working Group members via the newsletter and then published on the website.

Date

Title

Date: 21/04/2025

Title: Interplay between platelets and coagulation: from protective haemostasis to pathological arterial thrombosis
Date: 01/02/2025

Title: Anticoagulation in device-detected atrial fibrillation with or without vascular disease: a combined analysis of the NOAH-AFNET 6 and ARTESiA trials
Date: 01/12/2024

Title: Asundexian versus Apixaban in Patients with Atrial Fibrillation
Date: 01/06/2024

Title: Shortening DAPT in Acute Coronary Syndromes: An ULTIMATE Effort towards Omitting Aspirin?
Date: 01/04/2024

Title: Anticoagulation for patients with atrial fibrillation and chronic kidney disease: insights from XARENO
Date: 01/12/2023

Title: Reversible or irreversible, that is the question? The impact of reversibility of P2Y12 receptor inhibition on a thrombus formation.
Date: 01/04/2023

Title: Hypercoagulability and fibrinolysis assessment in acute myocardial infarction: focus on high risk patients
Date: 01/02/2023

Title: NOAC vs. Warfarin for antiphospholipid syndrome: a pattern emerging?
Date: 01/04/2022

Title: Biomarkers and thrombotic risk in COVID-19 patients: what is the current status of knowledge?
Date: 07/02/2022

Title: Antiplatelet therapy in conservatively managed spontaneous coronary artery dissection: is less better?
Date: 01/12/2021

Title: NOACS or VKA in the elderly: can we find the antithrombotic sweet spot? The ENVISAGE-TAVI AF trial
Date: 01/10/2021

Title: One Month Post-PCI DAPT May Be Enough in High-Bleeding-Risk Patients, but Insufficient after ACS: MASTER-DAPT & STOPDAPT-2 ACS trials
Date: 01/06/2021

Title: Expanding the use of Rivaroxaban in patients with atrial fibrillation and bioprosthtic mitral valve: RIvaroxaban for Valvular Heart dieseasE and atRial Fibrillation Trial- RIVER trial
Date: 29/01/2021

Title: Thromboembolic prevention with low-dose edoxaban in very elderly Japanese high-risk individuals with AF
Date: 22/01/2021

Title: The thrombotic nature of cardiac injury in subjects dying of COVID-19 infection
Date: 09/12/2020

Title: Defining the patients who will benefit most for antithrombotic treatment with dual pathway inhibition
Date: 30/06/2020

Title: Thrombomodulin as an early marker of endotheliitis in COVID-19